DailyIQ
|
Sector:HealthcareAll sectors
Last updated 13 minutes ago

MDLN·Medline Inc.

$.
+. (+.%)
After Hours
High
$41.05
Open
$40.41
Market Cap
53.91B
52W High
$50.88
Low
$40.00
P. Close
$41.05
P/E
55.81
52W Low
$32.81
Fwd P/E
24.63
DailyIQ Est.
$53.35
Technical Score (1D)
50
NEUTRAL
News Sentiment
77
BULLISH
MDLN announced a prime vendor agreement with Allina Health, giving the Minnesota‑based system access to Allina’s 12 hospital campuses and more than 90 clinics. The deal grants Allina full access to MDLN’s medical‑surgical product portfolio and distribution network, expanding MDLN’s footprint into Minnesota and Wisconsin. By securing a reliable supply channel, the partnership could lift MDLN’s order volume and contribute incremental revenue in the coming quarters. For the next 1–10 trading days, the market will focus on how quickly Allina integrates MDLN’s solutions into its procurement processes and whether early revenue guidance is adjusted upward. Analysts will watch for any updates to the expected incremental revenue from the partnership, as well as early signs of accelerated adoption. Investors should also monitor supply‑chain or logistics updates that could affect MDLN’s cost structure. Finally, keep an eye on Allina’s procurement announcements for confirmation of order volumes and timelines, which will help gauge the partnership’s immediate impact.
Earnings Summary
Medline Inc. (MDLN) is a global manufacturer and distributor of medical supplies, serving healthcare providers across the continuum of care. The company operates through Medline Brand, producing surgical solutions, frontline care items, and laboratory equipment, and Supply Chain Solutions, which offers logistics and procurement services. MDLN operates within the broader Healthcare sector, specifically the Medical Instruments & Supplies industry. In Q4 2025, MDLN reported an EPS of –$0.01 versus an estimate of $0.2537, marking a miss, while revenue of $7.787 billion exceeded the $7.698 billion estimate, indicating a revenue beat. The company’s earnings guidance for Q1 2026 is not yet released, so a direct comparison of EPS and revenue trends across the last two quarters cannot be made. With only one quarter of actual results available, it is not possible to determine a recent beat/miss pattern beyond the single miss in Q4 2025. Not enough information to assess YoY growth trajectory, historical beats or misses, or consistent patterns in revenue versus EPS performance. Recent developments include a prime vendor agreement with Allina Health, granting MDLN access to 12 hospital campuses and over 90 clinics, which could lift order volume and incremental revenue in upcoming quarters. The company has also secured leases for two new distribution centers in Northern California to replace a fire‑destroyed site, expanding its customer‑facing footprint by 45 percent and aiming to reduce supply‑chain risk. Jim Cramer’s endorsement on Mad Money has spurred a rally, but the company’s first‑quarter report showed a 26 percent drop in net income, raising margin concerns amid the distribution center rebuild. Investors should watch for the Q1 2026 earnings release to gauge whether revenue guidance is adjusted upward and whether EPS improves. Key will be early signs of accelerated adoption of the Allina partnership, updates on the new distribution centers’ operational readiness, and any commentary on margin recovery following the fire‑related disruptions.

EPS

EstBeatMiss
$-0.06$0.05$0.16$0.26$0.37Q4'25Q1'26
QtrEstActual+/−
Q1'26$0.32 - -
Q4'25$0.25$-0.01-103.9%

Revenue

EstBeatMiss
$7.7B$7.7B$7.7B$7.8B$7.8BQ4'25Q1'26
QtrEstActual+/−
Q1'26$7.7B - -
Q4'25$7.7B$7.8B+1.2%
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

MDLN Stock Snapshot

MDLN is currently trading at $40.09, giving Medline Inc. a market cap of 53.91B and a P/E ratio of 55.8. Today's range spans $40.00–$41.05, with shares opening at $40.41 and moving down $0.96 (2.3%) from the prior close. DailyIQ's technical score sits at 50/100 (HOLD) with a news sentiment reading of 77/100.

Over the past year MDLN has traded between $32.81 and $50.88 - the current price is +22.2% off the 52-week low and -21.2% from the high. 37 analysts cover the stock with a Buy consensus and a mean 12-month target of $51.15 (range $40.00–$62.00), implying upside of +27.6%.

Medline Inc. (MDLN) has 53.91B in Healthcare market capitalization and is currently neutral on the technical dashboard: 50/100, HOLD, price $40.09 (in the lower half of its 52-week range). Sentiment reads bullish at 77/100. (P/E: 55.8) In this tier, quiet accumulation often happens in HOLD phases - active managers who want to build positions without signaling do it here, where the price isn't trending and volume patterns are easier to hide. Annual range: $32.81–$50.88.

Portfolio construction in Healthcare often uses large-cap names like MDLN as tactical swing positions during neutral phases: cheap enough to overweight, liquid enough to exit quickly, and large enough to provide meaningful sector beta. The current 50/100 (HOLD) at $40.09 (in the lower half of its 52-week range) and bullish sentiment (77/100) frame the position as a catalyst play within the $32.81–$50.88 annual range rather than a directional bet.